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Attempting to Stop Antipsychotic Medication 
Abstract 
Purpose: To explore supports and coping strategies used during attempts to discontinue 
antipsychotic medication and test for associations with success.   
Method: 144 people who were taking or had taken antipsychotics completed The Experiences of 
Antipsychotic Medication Survey. Among them, 105 people had made at least one discontinuation 
attempt and answered a series of questions about their most recent attempt to stop. Content 
analysis and chi square tests of independence were used to categorise the data and explore 
associations. Success was defined as stopping all AM use irrespective of the duration of the 
medication-free period or whether relapse occurred, which were explored separately. 
Results:  Among the 105 people who had attempted discontinuation, 61.9% described unwanted 
withdrawal effects and 27.6% of the group described psychotic or manic relapse during the 
withdrawal period. Within this group 55% described successfully stopping all AM for varying lengths 
of time, half reported no current use, and half described having some form of professional, family, 
friend, and/or service-user or peer support for their attempt. Having support was positively 
associated with success and negatively associated with both current use, and relapse during 
withdrawal. A range of coping efforts were described, but having coping strategies failed to show 
significant associations with any of the dependent variables explored. Among those who described 
successfully stopping, some described returning to AM for short periods when needed while others 
reported managing well with alternative methods alone.   
Conclusions:  Findings cannot be readily generalised due to sampling constraints, but results suggest 
a wide range of supports and coping strategies may be used when attempting to discontinue 
antipsychotics. Many people may attempt to discontinue antipsychotics without any support. Those 
who have support for their attempts may be significantly less likely to relapse during withdrawal and 
more likely to succeed in their attempt. There is a pressing need for further research in this area. 
Keywords: Antipsychotics; Medication Withdrawal Syndromes; Psychoses Substance-Induced; 
Human Rights; Social Support; Coping Behaviour  
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Introduction 
It is well established that most people who take antipsychotic medication (AM) will attempt 
to discontinue them [1,2]. In one large sample, 74% had attempted to discontinue within 18 months 
of treatment initiation [1]. Other studies suggest many who stop eventually resume the medication 
[3], but that 30%-40% of people remain off antipsychotics long-term [4]. Withdrawal effects can 
span somatic, cognitive, and emotional domains, and symptomatic relapse is common [5,6], 
particularly in the first three months following discontinuation [7]. Longitudinal studies show it is 
possible for some people to stop taking AMs and experience equivalent or better recovery outcomes 
than those who persist with them, but that it can take several years for these favourable outcomes 
to appear [4,8,9]. Despite the high risk of relapse during withdrawal and the first years following 
discontinuation, many people make multiple attempts [3]and appear to persist with their goal to 
manage without AMs [4]. 
It is problematic to determine whether relapse during or proximal to discontinuation 
represents a withdrawal syndrome or the re-emergence of a chronic mental-health problem, or 
both. Some researchers hypothesise that relapse proximal to withdrawal is the result of neurological 
adjustments to the removal of, or reduction in, the dopamine blockade, which produce a 
subsequent surge of excitation [10-13]. Whatever the cause, relapse is a challenge faced by many 
people who attempt discontinuation.  
Relapse prevention is an admirable aim, but qualitative studies suggest service-users 
prioritise measures of quality of life and daily functioning over the presence or absence of symptoms 
alone [14]. It has been argued that “although certainly not desirable, a contained relapse is rarely 
the end of the world” [15, p 898]. Unfortunately, there is a lack of evidence regarding what helps 
people prevent or contain relapses. Much of the research has focused on clinical and medication 
factors and as such little is known about how people manage their attempts to stop or whether 
psycho-social factors like coping and support make a difference to their ability to successfully 
achieve their intended goal of discontinuing AMs, or prevent relapse during withdrawal.   
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There are no widely accepted guidelines for safely managing the withdrawal process, though 
several books and websites have been produced by experienced clinicians and service-user groups 
that suggest support and coping strategies are important [16-18]. Briefly resuming prior doses 
during the reduction process has also been described as potentially helpful [16]. This medication-
based coping strategy will be referred to as temporary or intermittent use here, and is distinguished 
from resuming maintenance treatment. A lack of information about what is needed to safely 
manage withdrawal effects poses practical and ethical considerations for treatment systems aiming 
to align their practice with the principle of informed consent. It is difficult to freely choose to persist 
with AMs without knowledge of how to stop them.   
Only two, small peer reviewed studies have explored how people cope during withdrawal 
from AMs. In the more recent of these, 12 people were interviewed about their decision to stop, 
their experience of attempting to stop, and their decision to resume or not [19]. Thematic analysis 
highlighted the importance of “weaving a safety net” to support wellbeing. Participants highlighted 
the value of building alliances with family, friends, and professionals, peer support, practical 
resources such as written indicators of relapse, access to talking therapy, relaxation skills, healthy 
lifestyles, access to information resources, and having knowledge of all these things [19].  
All twelve reported needing alternative strategies and tools for coping during and after 
withdrawal. Sometimes a return to AMs was needed when those strategies were not working. This 
suggests studies seeking to explore how people manage discontinuation need to be designed to 
capture those who intermittently use AMs to manage when alternative approaches prove 
insufficient alone and those who successfully stop and later return, alongside those who stop long-
term. In the larger of the two studies of subjective AM discontinuation experiences, a survey of 98 
people, a similar range of supports and coping strategies were described as being helpful, but 22% 
described making their attempt in isolation [20,21]. In both studies, a minority of participants were 
no longer taking AMs, 21% and two people respectively [19,21]. Coping strategies and supports are 
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clearly experienced as important to those who attempt to stop AMs, though it remains unknown 
how these affect discontinuation outcomes.   
One recent longitudinal discontinuation study found social integration was significantly 
predictive of improved recovery outcomes among people who had stopped taking AMs, but it is 
unclear whether those who have support for their attempt are more likely to successfully stop or not 
[9]. The only study to explore whether coping strategies and having support are associated with AM 
discontinuation found those who had stopped did not have significantly higher levels of support or 
use more effective coping strategies compared to those who persisted with AMs at the time they 
were interviewed [22]. Among the sample of 48 people diagnosed with schizophrenia spectrum 
disorders, 23 had successfully discontinued AMs. They did not explore the role of coping and support 
during the withdrawal process, which may represent a critical period in any attempt to discontinue 
AMs long-term. More research is needed to understand how these important psycho-social variables 
affect the success of attempts to discontinue AMs.    
Method 
This investigation aims to explore, with the largest sample to date, how people who attempt 
AM discontinuation manage during withdrawal and whether the availability of support and their 
personal efforts to cope are associated with successfully stopping. This study is based on responses 
to selected questions in The Experiences of Antipsychotic Medication Survey concerning people’s 
efforts to manage attempted discontinuation of AMs. The anonymous survey was available for 
online completion in 2014 [23]. Ethical approval for the study was granted by the University of 
Auckland Human Participants Ethics Committee.  
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Participants 
The online survey was open to New Zealand adults aged 18 years or older, who were taking, 
or had taken, AMs for at least three months, for any reason, and who were not currently residing in 
an in-patient unit. Recruitment was carried out through mainstream radio media and service-user 
networks across New Zealand. The entire sample answered questions about the experience of taking 
AMs, and whether they had contemplated or attempted stopping AMs (n=144). Only the 105 people 
who had made at least one attempt to stop taking AMs were presented with questions about 
attempted discontinuation, and form the sample of interest in the current investigation.   
Instrument 
The survey was constructed by adapting the survey used in the Experiences of 
Antidepressants Study [24], expanding it to include measures of quality of life and psycho-social 
resources, and an additional section exploring attempted discontinuation. Those who had made at 
least one attempt to stop taking AMs answered a series of questions about their most recent 
attempt to stop. Primary symptoms at first AM prescription were assessed via a check-list of major 
symptoms (hallucinations, delusions, mania, and depression) with the opportunity to specify others. 
Categories were collapsed to show how many people experienced the hallmark symptoms of 
psychosis or mania prior to starting AMs. Diagnosis was queried but responses did not provide 
sufficiently reliable information for further analysis and are not reported.  
Withdrawal methods were assessed using a sequence of questions that allowed for the 
verification of participants’ self-reported use of a gradual method, where only those who described 
reducing across more than one month were categorised as following a gradual withdrawal method.  
Coping efforts, support and the outcome of the attempt were evaluated with open-ended 
questions asking, ‘what did you do to cope with the unwanted effects of withdrawing from the 
medication?’, ‘what support did you have for your attempt to stop taking antipsychotic 
medication?’, and ‘what was the outcome of your most recent attempt to stop taking AMs?’ Success 
was evaluated by analysing outcome descriptions for references to stopping or resuming AM use. 
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Multiple choice questions assessed the length of time participants remained AM-free, 
current use of AMs (‘are you still taking oral antipsychotic medication?’), doctor consultation, 
whether any other advanced preparations were made, and whether they intermittently used the AM 
to cope during withdrawal. A multiple choice question from the medication experiences section of 
the survey asked participants to select when they had most recently taken AMs (response options 
ranging from ‘current use’ to ‘more than five years ago’). This item was designed to gauge the 
historic nature of medication experiences being reported, but was here used to provide further 
detail on the length of time participants discontinued AM for.  
Relapse during withdrawal was not directly queried in the survey and was assessed by 
analysing responses to the open questions about the effect of withdrawing from AMs (‘what were 
the effects of withdrawing from the medication?’) and the outcome of the attempt.  
Data Analysis 
Content analysis was used to categorise descriptions of the coping strategies people used, 
the support they had for their attempt, withdrawal effects, experiences of relapse during 
withdrawal, and the subjective success of their attempt. Coding was checked for reliability by two 
independent raters who used a written coding protocol to review and code 20% of the participant 
responses to each question. Discrepancies were discussed and definitions refined before the data 
was re-coded and again compared for discrepancies, resulting in a simple agreement rate of 96.7%.  
A deductive procedure was used to identify success, where those who described resuming 
AMs when asked about the outcome of their attempt were deemed unsuccessful and those who 
described stopping without resuming AMs soon after were categorised as successful, regardless of 
whether they were currently taking AMs or not, the length of time they remained off AMs, or 
whether they relapsed during the process or not, all of which were queried separately. Therefore, 
success should be read as a measure of whether people initially stopped taking AMs successfully, 
while current use provides a supplementary measure of whether they had sustained that result at 
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the time of survey completion, which is more directly comparable to other measures of success used 
in the existing studies [19,21,22].  
A similar deductive analysis was used to assess relapse during withdrawal. Relapse was 
defined as the emergence or re-emergence of psychotic or manic symptoms during or proximal to 
withdrawal, and was inferred from participant descriptions of withdrawal effects and 
discontinuation outcomes that directly referred to psychosis or mania, detailed symptoms of 
psychosis or mania, or explicitly referred to “relapse,” “getting unwell” or “hospitalisation” against a 
prior history of psychosis and/or mania. Psychotic symptoms were defined as voices and other 
hallucinations or perceptual disturbances, delusions and other unusual beliefs, and/or racing 
thoughts indicative of thought disorder. Mania was defined as a description of expansive mood, 
reduced need for sleep, uncharacteristic striving behaviour, and failure to meet a sufficient standard 
of self-care. References to relapse that occurred years after the withdrawal process were left 
uncoded. We use the term ‘withdrawal during relapse’ to emphasise that this measure of relapse is 
specific to the withdrawal period and does not include all experiences of relapse over time. 
Content analysis was used to categorise the availability of support and the level, sources and 
forms of support people reported. A code of no support was only assigned to participants who 
explicitly stated that support was not available to them. Each coping strategy participants described 
using during withdrawal was identified, similar strategies were grouped together and labelled 
accordingly. Those who explicitly described having no coping strategies were coded into a zero 
strategies group. For the purposes of statistical analysis, participants were then dichotomised into 
sub-groups distinguishing those who described having coping strategies from those who reported 
having no strategies or did not describe strategies. The methods used to assess relapse and 
dichotomise coping during withdrawal mean there is a high chance of false negatives and these 
results should be interpreted with particular caution. 
Pearson’s Chi Square tests were used to explore whether coping and support were 
associated with initial success (0 unsuccessful resumed, 1 successful stopped) and current use of 
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AMs (0 no current use, 1 current use). Two-by-two cross-tabulations were conducted for each of the 
independent variables of interest: consulting a doctor (0 No, 1 Yes), making preparations (0 No, 1 
Yes), having support (0 No, 1 Yes), intermittent use of AMs to cope during withdrawal (0 No, 1 Yes), 
use of any coping strategies excluding substance-use (0 No, 1 Yes) and use of personal thought- or 
behaviour-based coping strategies during withdrawal (0 No, 1 Yes). Follow-up analyses were carried 
out to evaluate associations with relapse during withdrawal (0 No, 1 Yes). To ensure groups were 
exhaustive, participants with missing data were excluded from the statistical analyses. Those who 
reported being in progress with their attempts to stop were excluded from statistical analyses. No 
cross-tabulations contained cells with expected counts below five, and the data met the 
assumptions required for Chi Square.    
Results 
Participants 
The participants were 105 New Zealand adults who had taken AMs for more than three 
months and had made at least one attempt to stop. The majority of the group was female, employed 
in paid or unpaid, part-time or full-time work or study, and of New Zealand European ethnicity 
(Table 1). Most participants reported taking other psychiatric medications alongside their most 
recent AM, and it is unknown when or if these medications were also discontinued.    
Table 1. Characteristics of the Sample who had Attempted to Stop Taking AMs   
Participant characteristics Count (%) Participant characteristics Count (%) 
Gender    Age of Primary Symptom Onset   
Female 78 (74.3%) Under 18 Years 45 (48.9%) 
Male 25 (23.8%) 18-29 Years 28 (30.4%) 
Gender Diverse 2 (1.9%) 30-39 Years 11 (12.0%) 
Ethnicity    40-49 Years 4 (4.3%) 
NZ-European 88 (83.8%) 50-65 Years 4 (4.3%) 
Maori or Part Maori 9 (8.6%) Age First Started AMs (mean 29 yrs; range 12-63 yrs) 
Other 8 (7.6%) Under 18 Years 15 (14.4%) 
Current age (mean 41 yrs; range 18-70 yrs) 18-29 Years 47 (45.2%) 
18-29 years 25 (23.8%) 30-39 Years 23 (22.1%) 
30-39 years 25 (23.8%) 40-49 Years 12 (11.5%) 
40-49 years 22 (21.0%) 50-65 Years 7 (6.7%) 
50-59 years 23 (21.9%) Most recent or current AM type(s)   
60-70 years 10 (9.5%) Typical AM Only 9 (8.8%) 
Occupational Status   Atypical AM Only 90 (88.2%) 
Not Employed 21 (20.0%) Both Typical and Atypical AM 3 (2.9%) 
Yes Employed 84 (80.0%) Polypharmacy – multiple simultaneous psych meds 
Highest level of education   No polypharmacy single oral AM only 22 (21.0%) 
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Did not complete high school 6 (5.7%) Yes Polypharmacy  76 (72.4%) 
Completed high school 10 (9.5%) Age at Last Attempt to Stop (mean 36 yrs; range 16-70 yrs) 
Diploma/cert. after high school 37 (35.2%) Under 18 years 1 (1.0%) 
University degree 52 (49.5%) 18-29 years 35 (34.3%) 
Hallmark Symptoms of Bipolar or Psychosis 30-39 years 27 (26.5%) 
Yes 84 (80.0%) 40-49 years 22 (21.6%) 
No 21 (20.0%) 50-70 years 17 (16.7%) 
This table presents the demographic and clinical characteristics of the subsample of survey participants who indicated 
making an attempt to stop taking AMs. Percentages are expressed as a proportion of the whole sub-sample of 105.  
 
Initial Success and Current Use  
When asked about the outcome of their most recent attempt to discontinue AMs, 55% of 
participants described stopping all AM use for some period of time and were coded into the 
Successful group. As shown in Table 2, at the time they completed the survey, 50.5% of the sample 
reported no current use of AMs, and 51.4% reported remaining off AMs for more than one year, and 
26.8% reported remaining off AMs for less than a month. While not the focus of this article, the 
qualitative outcome descriptions revealed some participants who successfully stopped periodically 
resumed AM use when their alternative approaches were proving insufficient alone. Those who 
described successfully stopping referred to improved or unchanged wellbeing, but the majority of 
those who described being unsuccessful in their attempts described a range of negative outcomes 
such as hospitalisation, increased suicidality, disrupted employment and relationships, and 
compulsory treatment orders.  
Table 2. Details of Most Recent Attempt to Discontinue AMs 
  Responses  Total (% n=105) 
Consulted a Dr 51 (48.6%) 
Made Other Advanced Preparations 64 (61.0%) 
Had Support  52 (49.5%) 
Intermittent AM Use to Cope  34 (32.4%) 
Withdrawal Method a  
Abrupt or swift withdrawal across one month or less   58 (55.2%) 
Gradual withdrawal across more than one month 34 (32.4%) 
Multiple Attempts  
First attempt to stop 37 (35.2%) 
Previous attempts to stop 67 (63.8%) 
Relapse during Withdrawal  (Psychosis, Mania and/or Hospitalisation) b  
Yes, Described Relapse  29 (27.6%) 
No, Did Not Describe Relapse  68 (54.8%) 
Success   
Stopped – Successful  58 (55.2%) 
Resumed – Unsuccessful  37 (35.2%) 
In Progress or Uncoded 10 (9.5%) 
Time off AMs   
< 1 month 28 (26.8%) 
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As shown in Table 3, among those who were currently taking AMs (and were not still in 
progress with their attempts; n=48), 14.6% reported remaining off AMs for over a year (n=7), 4.2% 
for six to twelve months (n=2), 29.2% for one to six months (n=14) and 52.1% reported having 
remained off AMs for less than one month (n=25). Among those who were not currently taking AMs 
at the time they completed the survey (n=53), 88.7% reported having remained off AMs for over a 
year (n=47), 7.5% for six to twelve months (n=4), and 3.8% for one to six months (n=2). No-one in 
this group reported remaining off AMs for less than one month. Of those who stopped for more than 
a year and reported no current use (n=47), 42.6% had most recently used AM more than five years 
ago (n=20), 21.3% three to five years ago (n=10), 29.8% had most recently used AM one to two years 
ago (n=14) and 6.4% reported most recently using AMs within the last year (n=3).   
Table 3. Distribution of the Data across Relapse, Success, and Current Use Groups 
 Relapse Success  Current Use 
No (n=64) Yes (n=29) No (n=37) Yes (n=58) No (n=53)  Yes (n=48) 
Years Start to Stop  7.73 8.31 7.27 7.40 6.25 10.38 
Gender       
Female (n=75) 51 18 24 49 42 33 
Male (n=24) 12 10 12 9 10 14 
Other (n=2) 1 1 1 0 1 1 
Initial Primary Symptoms        
Psychosis, No Mania (n=28) 15 12 9 17 14 14 
Psychosis and Mania (n=32) 19 10 14 16 15 17 
Mania, No Psychosis (n=20) 16 2 5 14 12 8 
Other Sx Only (n=21) 14 5 9 11 12 9 
Hallmark Symptoms of Mania and/or Psychosis a     
No (n=21) 14 5 9 11 12 9 
Yes (n=80) 50 24 28 47 41 39 
Consulted a Doctor a        
No (n=53) 27* 21* 22 26 25 28 
Yes (n=48) 37* 8* 15 32 28 20 
Made Other Preparations a       
No (n=29) 17 9 12 16 16 13 
Yes (n=60) 41 16 19 37 33 27 
1 – 6 months 16 (15.2%) 
6 – 12 months 7 (6.7%) 
More than a year 54 (51.4%) 
Current AM Use  
Yes Current Use of AMs 52 (49.5%) 
No Current Use of AMs 53 (50.5%) 
Withdrawal methods, doctor consultation, intermittent use of AMs to cope during withdrawal, time off AMs, success, 
and current AM use for the whole sample (n=105). (a) Excludes those who selected ‘Do Not Remember’ from the 
multiple-choice options or described not knowing how long they took to withdraw; (b) Participants who described 
relapse of psychosis, mania or hospitalisation as effects or outcomes of their attempt to withdraw from AMs were coded 
into the Relapse group. Those who described other effects and outcomes but did not describe relapse of psychosis, 
mania or hospitalisation were coded into the No Relapse Described group. Eight participants gave ambiguous responses 
that were left uncoded and total does not sum to 100%.  
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Had Support a       
No (n=52) 25* 21* 25* 24* 21* 31* 
Yes (n=49) 39* 8* 12* 34* 32* 17* 
Described 1> Coping Strategies a      
No (n=46) 26 16 20 23 20 23 
Yes (n=54) 38 12 16 35 20 21 
Intermittent Use During Withdrawal a      
No (n=69) 51* 11* 14* 50* 45* 24* 
Yes (n=32) 13* 18* 23* 8* 8* 24* 
Time Off AMs       
< 1 month (n=25) 9 15 24 1 0 25 
1 – 6 months (n=16) 7 9 11 2 2 14 
6 – 12 months (n=6) 5 0 1 4 4 2 
More than a year (n=54) 43 5 1 51 47 7 
This table presents the distribution of the data across the three outcome groups of interest, self-reported 
relapse during withdrawal, success of the attempt, and current use of oral antipsychotics, excluding those who 
were in progress with their attempts (n=4) and those who had missing data on either variable; rows and/or 
columns do not always sum to 100% of the stated subgroup size (in brackets). a) Two-by-two Pearson Chi 
Square Tests of Independence were conducted for all dichotomous, categorical variables displayed here.  
* Statistically significant difference; all p values < 0.05.  
 
Experiences of Withdrawal 
Details of the participants’ most recent attempt to discontinue AMs and rates of success 
they reported are summarised in Table 2. When asked about the effects of withdrawal, 61.9% 
reported experiencing unwanted withdrawal effects across the full-range of physical, emotional, 
cognitive, and functional domains. Relapse in the form of psychosis, mania, or hospitalisation was 
described by 27.6% of the group at the time of withdrawal. Within the physical domain, 21.0% 
described insomnia or disturbed sleep. Within the emotional domain, a small group of five people 
reported suicidal thoughts, urges and/or acts. Additionally, 2.9% of the group specified that the 
negative withdrawal effects were short-lived for them, 18.1% specified they experienced zero 
withdrawal effects, and 13.3% reported only positive withdrawal effects, including improvements in 
cognitive clarity and energy levels.  
The Availability of Support 
Half the group (49.5%) reported some form of support from at least one professional, family 
member, friend, or other social contact. Specific sources of support included family members and 
spouses (n=22), prescribers (n=13), friends and colleagues (n=9), social workers, nurses and case-
workers (n=4), therapists and counsellors (n=9), peer support groups and online networks (n=4), 
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mental-health services in general (n=4), and a range of others (n=5) including telephone help lines 
for example: 
“Support of long-term therapist, doctor (GP) and others was essential.”  
“Support from wife to encourage walking, breathing, healthy eating, re-framing negative 
experiences and visualising a positive future.”  
“Family supported me by allowing me to stay with them, helped me with cooking, 
encouraging me to exercise, reassuring me.”  
 “I joined an internet support group which gave me confidence that there were others like me 
[…] They were peers that I could talk to, receive encouragement from, and I could encourage 
them too.”  
The level of support described varied, with only one source of support reported by 14.3% 
(n=15) of the sample, two supports reported by 21.9% (n=23), and 9.5% describing three or more 
sources of support (n=10).  Some described personal barriers to seeking help from their available 
supports, or having to convince people to support them in their efforts. Half of the group (50.5%) 
reported feeling they had no support for their attempt; some kept their attempt a secret to avoid 
discouraging reactions from others or faced barriers to help-seeking. 
 “No support, just decided to do it on my own. [I] thought others would advise against this.”  
“People in my life knew that it was my plan, but I was too proud to ask for help [...]”  
Several forms of support were described. These were encouragement, validation and 
reassurance (n=9), someone to talk to about the experience (n=5), the provision of somewhere to 
stay (n=4), support with activities of daily living (n=3), information to understand withdrawal (n=3), 
assistance with self-monitoring (n=2), support to use healthy coping strategies (n=2) and access to 
other medications to take as needed (n=1).  
Supports were reported by 58.6% of the 58 who described successfully stopping AMs and 
32.4% of the 37 who resumed. Results of Pearson’s Chi Square Test showed support held a small but 
significant positive association with success (phi=.256, p=.013, n=95) and a small but significant 
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negative association with current use (phi=-.249, p=.012, n=101). Table 3 shows those who had 
support were more likely to describe successfully stopping and less likely to report current use of 
AMs. There was a significant, negative association of moderate magnitude between support and 
relapse of psychosis or mania during withdrawal (phi=-.309, p=.003, n=93). People who had support 
reported psychotic or manic relapse during withdrawal significantly less often than those without 
support.  
Preparing to Stop 
Almost half the group (48.5%) reported consulting a doctor in preparation of their attempt 
(Table 2). Nearly two thirds indicated making other advanced preparations, listed in Table 4. 
Consulting a doctor showed no significant association with success, or current use, but did show a 
small, significant negative association with relapse during withdrawal (phi=-.280, p=.007, n=93). 
Making any other preparations showed no significant association with success, current use, or 
relapse during withdrawal. 
Table 4 Advanced Preparations for Most Recent Attempt to Discontinue AMs  
Response Options  Total (%) n=105 
Gathering information about withdrawal  33 (31.4%) 
Informing family, partner or spouse of plans to stop and support needs  33 (31.4%) 
Making a plan for gradual withdrawal before making any changes  32 (30.4%) 
Establishing a stable, regular daily routine  25 (23.8%) 
Reducing environmental stressors  24 (22.9%) 
Establishing a regular sleeping pattern  19 (18.1%) 
Seeing a counsellor, psychologist or psychotherapist  18 (17.1%) 
Informing friends of plans to stop and support needs  17 (16.2%) 
Creating a formal advanced directive  14 (13.3%) 
Stopping or reducing use of illicit drugs   13 (8.6%) 
Taking time off work or study  9 (8.6%) 
Learning meditation  7 (6.7%) 
Arranging a safe, quiet place to go in case the need arose  7 (6.7%) 
Stopping or reducing use of alcohol  5 (4.8%) 
Joining a support group  3 (2.9%) 
Those who reported making advanced preparations (61%) were asked to select from a check-list all of the 
advanced preparations they made for their most recent attempt to stop (additional to consulting a doctor 
which was queried separately first). Percentages are expressed as a proportion of the total sample of 105. 
 
Intermittent Use during Withdrawal 
Approximately one third (32.4%) reported intermittent use of AMs to manage the effects of 
withdrawal. There was a large, significant negative association between intermittent use to cope 
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during withdrawal and success (phi=-.503, p=.000, n=95) and moderate, positive associations with 
both relapse during withdrawal (phi=.410, p=.000, n=93), and current use (phi=.375, p=.000 n=101).   
Coping Strategies Used during Withdrawal 
Most people (75.2%) provided a description of their use of coping strategies. These are 
detailed in Table 5. Around a sixth of the sample (17.1%) described using no coping strategies, 
including seven who reported experiencing negative withdrawal effects, four who reported positive 
withdrawal effects, seven who reported zero withdrawal effects, and one who could not recall the 
withdrawal effects they experienced. In addition, 30.5% (n=32) named one coping strategy, 17.1% 
(n=18) named two to three strategies, and 4.8% (n=5) named four or more coping efforts together 
(range 0-7). 
 
Table 5 Coping Strategies Used During Withdrawal a   
Content categories Total (%) n=105 
Personal Strategies 38 (36.2%) 
- Psychological Strategies 37 (35.2%) 
- Health Behaviours  12 (11.4%) 
Nothing or No Coping Strategies b 18 (17.1%) 
Support Strategies  13 (12.4%) 
Medication Strategies 9 (8.6% 
Environmental Strategies 8 (7.6%) 
Substance Use Strategies 8 (7.6%) 
Other 4 (3.8%) 
Do Not Remember 4 (3.8%) 
Uncoded 22 (21.0%) 
This table presents (a) the full list of major content categories referenced in participant descriptions of 
coping during withdrawal, and (b) Nothing or No Coping Strategies includes those who did and did not 
experience withdrawal effects. 
 
Personal Strategies were defined as the use of thought-based and/or behaviour-based 
activities for managing withdrawal experiences. Within this category, one group of responses 
described health behaviours (n=12) and comprised exercise and walking (n=8), eating well and 
drinking water (n=4), and one reference to taking supplements. 
A second group of responses described the use of psychological strategies (n=37) aimed at 
curbing the difficult aspects of the process, including activities for self-care and comfort (n=14), 
attitudinal factors of determination, willpower and perseverance (n=9), distraction (n=7), 
meditation, mindful breathing and prayer (n=6), routine and living life (n=5), therapy techniques 
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(n=3), and self-expression (n=3). Activities for Self-Care and Comfort comprised Getting Extra Rest 
(n=9), Showers and Baths (n=3), Herbal Teas (n=2), Heat Bags (n=1), Personal Grooming (n=1) and 
Sleep Hygiene (n=1).  
 “Had lots of baths. Cried. Created. Prayed. Psychology appts. Ate well. Held on for dear life.”  
 “Holding on to the hope that things will get better and these are only side effects from the 
medication withdrawal.”  
Medication strategies were defined as the use of a medicine, pill or tablet to curb unwanted 
withdrawal effects; this could include temporary or intermittent use of the AM agent that was the 
target of the withdrawal attempt. This is distinguished from resuming maintenance treatment with 
AMs, which was considered an outcome statement about success and was not coded as a coping 
attempt. A few participants described intermittent Benzodiazepine Use (n=3/105; 2.9%) and Pain 
Relief (n=3/105; 2.9%). One participant noted using Antihistamines for itches (1%), two people 
reported the use of Sleeping Pills (1.9%), and two described using low-dose AMs on an as-needed 
basis (1.9%).  
Environmental strategies involved the use of environmental-modification or stimulus control 
as a method for managing the effects of withdrawal. Participants described Creating a Safe, Low-
Stress Environment (n=5/105; 4.8%), and Avoiding Stressful Environments (n=4/105; 3.8%), for 
example:  
“[I] made sure I was in a safe place with people who loved me”  
“Avoided going into public places”  
Support strategies referred to using support from Therapists and Counsellors (n=6/105; 
5.7%), Psychiatrists or Doctors (n=3/105; 2.9%), Family or Spouse (n=3/105; 2.9%) and Other 
Supports (n=2/105; 1.9%) including one reference to Support Groups and one nonspecific report of 
‘others’. Family or Spouse support strategies referred to talking and communication, staying with 
family and having a sense of connection with loved ones. Substance-Use Strategies comprised 
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Drinking Alcohol (n=3/105; 2.9%), Smoking Cigarettes (n=3/105; 2.9%) and Taking Drugs (n=3/105; 
2.9%), for example:  
“Whatever I felt was needed, smoked a bit of weed”.  
Within the ‘other’ category two participants reported coping with AM withdrawal effects via 
self-harm and/or suicidal behaviour. 
As seen in Table 3, grouping personal, environmental, support, and medication strategies 
together to reflect the use of any coping strategies, and excluding those who reported coping via 
substance-use, failed to show statistically significant associations with success (p=.133), current use 
(p=.078), or relapse during withdrawal (p=.143). Only the use of personal coping strategies was 
individually explored for statistical associations with the chosen measures of success. There were no 
significant associations between the use of personal coping strategies (health behaviours and 
psychological strategies) and success (p=0.054), current use (p=0.330), or relapse during withdrawal 
(p=.291).   
Discussion 
This cross-sectional survey of 105 people’s most recent attempts to stop taking AMs 
represents only the third, and largest, study to date that specifically explores the way people 
manage attempted discontinuation of AMs, and how those efforts affect the success of their 
attempts. Participants were disproportionately New Zealand European, female, educated beyond 
high-school, and employed, suggesting results may not be readily generalised to all who attempt to 
discontinue AMs.  
Support and coping appear potentially relevant to people across ethnic groups, gender 
identities, levels of education, and employment status, but it is important to keep in mind that these 
groups may have different needs and approaches that are not captured by participants in this 
sample. A comparable study with a similar sample size and a much more even gender distribution 
had very similar qualitative findings [20], which lends some tentative confidence to the current 
results.  
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Success and current use 
In this sample, 55% had successfully stopped AMs for varying periods of time, and 50.5% 
were not taking AMs at the time they completed the survey. This is similar to the only other 
comparable qualitative study [21], though naturalistic studies report lower rates of success between 
30-40% at long-term follow-up [4]. The majority of those who stopped successfully and had no 
current use reported remaining off AMs for over a year, while 37.7% of those with no current use 
had most recently used AMs more than five years ago. A small minority among those who were 
successful and reported no current use (n=6) had only recently stopped within the past six months, 
and the literature suggests a strong likelihood that at least some of these people will relapse and 
resume AMs for at least a short time in the future [4,9]. The literature also suggests that among 
those who were unsuccessful some will likely make repeat attempts to discontinue [20] and that 
some of them may succeed [3].  
Withdrawal experiences 
Most of the group experienced unwanted withdrawal effects during the period of reduction, 
consistent with the literature [20], but only 27.6% described experiences that met criteria for relapse 
during withdrawal. This is substantially less than the 50%-77% rates reported in meta-analyses of 
randomised controlled trials [25,26]. This is likely because the rate reported here refers to relapse 
within the withdrawal period only, and does not include relapses that occurred in the initial years 
following discontinuation. The use of definitions requiring varying thresholds of severity may also 
partially explain this difference; when our definition of relapse during withdrawal was expanded to 
include those who reported lesser forms of symptom exacerbation during withdrawal the figure 
increased to an equivalent 52%. It is unknown whether the relapse events described here result 
from the mechanisms of withdrawal, the re-emergence of a mental-health condition or an 
interaction with other factors like unrelated stressful events, and it is not within the scope of this 
investigation to explore this debate. Regardless of their cause, in this group, descriptions of 
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symptom exacerbation and relapse during the withdrawal period were common difficulties that 
participants had to face as part of their attempt to discontinue.    
Support for Attempted Discontinuation 
Half of the sample reported having support for their attempt to stop. Perhaps the most 
important finding is a small but significant association between support and both successfully 
stopping AMs and maintaining discontinuation. Those who had support were more likely to describe 
successfully stopping, and less likely to report current use of AMs at the time they completed the 
survey, suggesting that having support for attempted discontinuation may improve the likelihood of 
successfully stopping. However, it is also possible that other unmeasured variables, of which there 
are many, may account for the associations observed here. The qualitative data suggests having 
support provides a source of encouragement and hope alongside practical assistance with daily 
living, employing healthy coping strategies, and managing the reduction process.  A significant 
negative association between support and relapse during withdrawal strengthens the conclusion 
that having support may improve the likelihood of success and is consistent with the results of 
research showing social integration is a predictor of improved functional recovery outcomes 
following discontinuation [9].  
Discontinuation outcomes are often conceptualised as simple by-products of medication-
factors, diagnostic prognosis, and the withdrawal method used to manage the taper. In this group, 
discontinuation outcomes are also associated with having support for the attempt from other 
people. This suggests that overtly providing support to people who would like to stop AMs may 
improve their chances of success. It has been said that people seeking to recover from severe 
mental-health problems like psychosis “need the encouragement and support of an ally and an 
advocate, rather than the distanced and dispassionate insights of a neutral observer” [27, p 108]. 
This also appears to be true for people who take AMs and would prefer to stop. The associations 
observed here were statistically small in magnitude, but qualitatively important. Of course the 
effectiveness of any support relationship rests on interactions between environmental 
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opportunities, and multiple people, who each may be more or less able to give or receive support as 
it is needed during withdrawal or in the event of relapse.  
In line with other studies [19-21,28], the current investigation suggests people may 
frequently make their attempts with little to no support, and may deliberately withholding 
information about their attempt from prescribers and family members in fear of receiving 
discouraging responses, similar to the results of other studies [19,20,29]. The current results suggest 
this may hinder their chances of successfully discontinuing. Having support was associated with 
reduced relapse during withdrawal, and may help reduce the risks associated with attempting 
discontinuation. Given that it was possible for many to stop long-term (51% of the sample stopped 
for over one year) and maintain wellbeing without AMs, the current results strongly support the 
arguments made by other researchers [16,30-32], consumer rights legislation [33], and the service-
user movement [34-37], that people should have the choice to take AMs or not take them, the 
choice to change their minds later, and all the information and resources required to make choices 
that are safe and have the best possible outcome for their recovery.  
Efforts to Manage Withdrawal Effects 
Efforts to manage withdrawal began well before the withdrawal process for many people, 
with half consulting a doctor and most making other advanced preparations for their attempt. 
Around a third of the sample reported brief intermittent use of AMs during withdrawal and some 
described intermittent use as one of the ways they coped after successful discontinuation when 
their other efforts were proving ineffective. Intermittent use of AMs to cope with the effects of 
withdrawal was significantly associated with relapse during withdrawal and resuming maintenance 
treatment with AMs. It seems unlikely that intermittent use caused greater rates of relapse. Those 
who intermittently returned to previous doses during withdrawal potentially did so because they 
were already experiencing relapse. Other authors have suggested briefly returning to a previous 
dose may help prevent relapse from resulting in hospitalisation [16,19]. Intermittent use during 
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withdrawal may help curb the negative consequences of an unsuccessful attempt, but in this group 
did not prevent relapse or improve the likelihood of successful discontinuation. 
Results did not support statistically significant relationships between successful 
discontinuation or current use and consulting a doctor, making other advanced preparations, or use 
of coping strategies during withdrawal. Though they do not here share direct associations with 
success and relapse, these efforts to manage may yet be associated with other unmeasured 
outcomes like the degree of distress experienced. In addition, the nature of the coping strategies 
people used, the preparations they made, and the guidance they received as a result of efforts to 
consult a doctor may be more influential than whether any effort was made at all. For instance, 
avoidant and active or approach-focused coping strategies have been shown to have different 
effects on a range of measures of wellbeing when they are used habitually [38], and to bear 
divergent predictive relationships with QOL, both among those who take AMs and those who have 
stopped taking them [23]. People in this study described using a range of active, or approach-
focused, coping strategies involved in self-care, self-soothing, expression, physical health, and help-
seeking, as well as a range of avoidant coping strategies such as distraction, and isolation, which 
would conceivably have quite different effects on their internal experiences and the consequences 
of the withdrawal effects they face. There is a pressing need for further research in this area.  
Limitations 
The survey involved a relatively small sample, with demographic characteristics that differ 
from the general NZ population and other existing studies [9,19,20]. People residing within inpatient 
units and those without internet access were unable to participate. The sample was predominantly 
educated and employed. An over-representation of women and people of NZ-European ethnicity 
means results may neglect areas of specific relevance to men, people with other gender identities, 
and those from other ethnic groups. We have attempted to explore whether there are any 
differences in the attempts of those who successfully stopped and those who resumed. However, 
the results may be affected by the small sample size and sub-groups within it.  
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Interpretation of the results of statistical tests based on results obtained via content analysis 
is made fraught by the strong possibility that people neglected to mention topics of relevance when 
responding to open-ended questions, particularly with regard to relapse during withdrawal, which 
was not queried directly, and coping behaviours which are often carried out automatically without 
awareness of the decision to act in one way or another. Tests of statistical association were based on 
simple two-by-two cross-tabulations and other variables may account for the associations observed 
here. More research is needed to explore whether associations between support and successful AM 
discontinuation hold when other variables like withdrawal method and medication factors are taken 
into consideration.  
Those who reported successfully stopping and no current use had remained AM-free for 
variable periods of time, including those who had last used AMs more than five years ago, and those 
who had last used them less than a year ago. Associations reported here do not speak to how long 
people were able to remain AM free.   
This study lacked measures for symptom severity, diagnostic factors, AM dose, duration of 
continuous treatment, continuing use of other medications during or after AM withdrawal, and 
contextual stressors, which may also affect the success of attempted discontinuation. Polypharmacy 
was common in this group, but it is unknown whether people continued to take additional 
psychiatric medications during withdrawal from AMs.  
Further research with larger samples, standardised measures, and control variables are 
required to more systematically explore how people cope during withdrawal, and what forms of 
support, consultation, advanced preparations and coping methods variously help and hinder 
people’s chances of success. There is a need to extend the research to consider the impact of 
contextual stressors and internal resources known to affect mental health. This study suggests AM 
discontinuation outcomes may be affected by people’s support networks and highlights the 
important role that connection with encouraging others can play in the safety and success of efforts 
to discontinue AMs. Improving support for AM discontinuation may enable people to attempt 
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withdrawal more safely and with a greater likelihood of success.  Individual outcomes and efforts to 
manage may vary, but they do not appear to rest entirely on the individual alone.  
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